相关临床试验
1329
139 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1908
终止
63
4.7%
招募中
176
13.2%
暂停
6
0.5%
撤回
61
4.6%
进行中（未招募）
44
3.3%
Unknown
187
14.1%
已完成
697
52.5%
Enrolling By Invitation
12
0.9%
尚未招募
83
6.3%
暂无批准数据
- Canada announced the hiring of 64 scholars supported by more than C$500 million ($350 million) over eight years through its Global Impact+ Research Talent Initiative. - Forty-eight of the recruited academics come from US institutions including Harvard, Cornell, and MIT, spanning medicine, engineering, and climate science. - Researchers cited frozen federal grants and concerns over academic freedom under the Trump administration as key factors driving their departure. - The initiative is part of a C$1.7 billion ($1.2 billion) effort to attract world-leading researchers to Canadian universities.
- UBC Faculty of Medicine researchers secured more than $5.8 million through the NSERC Discovery Research Program to advance discovery research across multiple disciplines. - The funding is part of a $630 million total federal investment, with $47.6 million allocated to 199 new UBC-led programs and projects. - Funded projects span brain health, biomedical engineering, gene therapies, pain genetics, AI-driven mental health care, and cell and gene therapy bioprocessing. - Discovery Grants provide long-term support for ongoing research programs, with early career researchers receiving additional Discovery Launch Supplements of $12,500.
- A comprehensive Lancet review of billions of administered doses confirms mRNA vaccines are 87% effective against documented SARS-CoV-2 infection, 93% against hospitalization, and 94% against death within 14–42 days post-vaccination. - Serious adverse events including myocarditis (12.6–35.6 cases per million doses) and anaphylaxis (4.7 per million) remain exceedingly rare, with risks far lower than those from SARS-CoV-2 infection itself. - Protection waned over time and against the Omicron lineage (67% against infection, 72% against hospitalization), but booster doses restored much of the lost immunity. - Researchers highlight the platform's future potential beyond infectious diseases, including personalized cancer vaccines, influenza, RSV, and autoimmune conditions, while calling for equitable global access through technology transfer and local manufacturing.
- Two studies in Nature Communications identify gut fungi as key players in immune dysregulation and pediatric allergic diseases, including asthma and atopic dermatitis. - Analysis of over 2,200 samples from 1,400 infants shows specific fungal species like Malassezia and Saccharomycetaceae follow distinct developmental trajectories in the first year of life. - Early-life antibiotic exposure was found to disrupt the gut mycobiome, allowing fungal species such as Malassezia to flourish and directly affect immunological function. - Researchers suggest gut fungi may serve as both biomarkers for identifying at-risk children and promising targets for novel therapeutic interventions.
- SonoMotion announced that its Break Wave Pivotal S.O.U.N.D Clinical Trial met co-primary efficacy and safety endpoints for non-invasive kidney stone treatment. - The Break Wave device uses low pressure focused ultrasound to fragment kidney stones without anesthesia or sedation, allowing patients to remain fully awake during treatment. - The company received FDA 510(k) clearance for a next-generation Break Wave device featuring 31% smaller therapy probes and significantly reduced weight. - Full trial results will be presented at the American Urological Association annual meeting on May 16, 2026, as part of the practice-changing clinical trials program.
- Redwood AI Corp. has launched a collaborative research project with the University of British Columbia's Brent Page Lab to develop novel drugs for Alzheimer's disease targeting the NUDT5 protein. - The initiative combines Redwood's AI-driven computational platform with the Page Lab's medicinal chemistry expertise to design and optimize inhibitors for neurodegeneration-associated biological stress signaling. - The project aims to accelerate early-stage drug discovery by generating virtual compound libraries and identifying novel candidates with promising safety and efficacy profiles. - With over 55 million people worldwide living with dementia and a new case arising every 3 seconds globally, this collaboration addresses one of the most urgent unmet medical needs in healthcare.
- A randomized clinical trial of 399 adults found that fluvoxamine, a widely available antidepressant, significantly reduced fatigue and improved quality of life in long COVID patients. - The study showed a 99% probability that fluvoxamine outperformed placebo, while metformin showed no meaningful benefit for established long COVID fatigue symptoms. - Researchers used an innovative Bayesian adaptive design that allowed the trial to reach conclusions more efficiently than traditional clinical trials. - The findings represent one of the first evidence-based treatment options for long COVID fatigue, a condition affecting an estimated 65 million people worldwide.
- ALZpath's proprietary pTau217 antibody was featured across 29 presentations at the 2026 International Conference on Alzheimer's and Parkinson's Diseases, demonstrating its high diagnostic accuracy and disease specificity. - The antibody's platform-agnostic design enables seamless integration across diverse laboratory infrastructures, with leading in-vitro diagnostic companies selecting it as the basis for blood-based assay development. - The widespread adoption reinforces pTau217's position as the preferred antibody for scalable, high-performance Alzheimer's testing, addressing the projected 152 million global dementia cases among adults aged 65+ by 2050.
- Ty Sperle, a 19-year-old from British Columbia, became the first person in the world to be cured of chronic granulomatous disease through prime editing gene therapy in a breakthrough clinical trial. - The treatment involved extracting Sperle's own cells, correcting the genetic "spelling mistake," and reinfusing them back into his body where they multiplied and restored proper immune function. - The successful cure eliminates Sperle's need for daily antibiotics and antifungal medications while removing the constant threat of life-threatening infections that characterize this rare genetic condition. - The results, published in the New England Journal of Medicine, represent a significant advancement in gene editing technology and offer hope for treating other rare genetic diseases.
- A University of Calgary-led randomized controlled trial found that time-restricted feeding significantly reduced Crohn's disease activity by 40% and abdominal discomfort by 50% in just 12 weeks. - The 35-participant study showed that eating within an 8-hour window led to weight loss of 5.5 pounds and improvements in inflammatory markers without requiring calorie restriction. - Participants experienced a 40% reduction in stool frequency and notable improvements in blood markers including lower levels of leptin and PAI-1. - The research suggests intermittent fasting may offer a practical adjunctive strategy for Crohn's disease management alongside standard medical therapy.
